Literature DB >> 25511158

Recurrence patterns and survival endpoints in women with stage II uterine endometrioid carcinoma: a multi-institution study.

Mohamed A Elshaikh1, Zaid Al-Wahab2, Haider Mahdi3, Kevin Albuquerque4, Meredith Mahan5, Siobhan M Kehoe6, Rouba Ali-Fehmi7, Peter G Rose3, Adnan R Munkarah8.   

Abstract

OBJECTIVE: There is paucity of data in regard to prognostic factors and outcome of women with 2009 FIGO stage II disease. The objective of this study was to investigate prognostic factors, recurrence patterns and survival endpoints in this group of patients.
METHODS: Data from four academic institutions were analyzed. 130 women were identified with 2009 FIGO stage II. All patients underwent hysterectomy, oophorectomy and lymph node evaluation with or without pelvic and paraaortic lymph node dissections and peritoneal cytology. The Kaplan-Meier approach and Cox regression analysis were used to estimate recurrence-free (RFS), disease-specific (DSS) and overall survival (OS).
RESULTS: Median follow-up was 44months. 120 patients (92%) underwent simple hysterectomy, 78% had lymph node dissection and 95% had peritoneal cytology examination. 99 patients (76%) received adjuvant radiation treatment (RT). 5-year RFS, DSS and OS were 77%, 90%, and 72%, respectively. On multivariate analysis of RFS, adjuvant RT, the presence of lymphovascular space invasion (LVSI) and high tumor grades were significant predictors. For DSS, LVSI and high tumor grades were significant predictors while older age and high tumor grade were the only predictors of OS.
CONCLUSIONS: In this multi-institutional study, disease-specific survival for women with FIGO stage II uterine endometrioid carcinoma is excellent. High tumor grade, lymphovascular space invasion, adjuvant radiation treatment and old age are important prognostic factors. There was no significant difference in the outcome between patients who received vaginal cuff brachytherapy compared to those who received pelvic external beam radiation treatment.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Brachytherapy; Endometrial carcinoma; Hysterectomy; Prognosis; Recurrence; Stage II

Mesh:

Year:  2014        PMID: 25511158     DOI: 10.1016/j.ygyno.2014.12.012

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  3 in total

1.  Survival Outcomes Improved in Contemporary Cohort of Patients With Pelvic or Abdominal Recurrence After Treatment for Stage I/II Endometrial Carcinoma.

Authors:  Melody J Xu; Christina Chu; Stephen Rubin; Lilie L Lin
Journal:  Am J Clin Oncol       Date:  2017-12       Impact factor: 2.339

2.  Treatment outcomes of patients with stage II pure endometrioid-type endometrial cancer: a Taiwanese Gynecologic Oncology Group (TGOG-2006) retrospective cohort study.

Authors:  Hung Chun Fu; Jen Ruei Chen; Min Yu Chen; Keng Fu Hsu; Wen Fang Cheng; An Jen Chiang; Yu Min Ke; Yu Chieh Chen; Yin Yi Chang; Chia Yen Huang; Chieh Yi Kang; Yuan Yee Kan; Sheng Mou Hsiao; Ming Shyen Yen
Journal:  J Gynecol Oncol       Date:  2018-05-15       Impact factor: 4.401

3.  The influence of neighborhood socioeconomic status and ethnic enclave on endometrial cancer mortality among Hispanics and Asian Americans/Pacific Islanders in California.

Authors:  Julie Von Behren; Renata Abrahão; Debbie Goldberg; Scarlett Lin Gomez; Veronica Wendy Setiawan; Iona Cheng
Journal:  Cancer Causes Control       Date:  2018-07-28       Impact factor: 2.532

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.